Next-Generation Immunotherpeutics – Selective Recruitment of γδ T Cells by Bispecific Antibodies

Time: 4:30 pm
day: Day One


• Immunotherapeutic approaches for redirecting pan CD3+ T cells to target cancer is under clinical investigation
• Prototypic bispecific antibody concurrently binds to the Vγ9 chain of the Vγ9Vδ2+γδT cells and to tumor antigens for efficient lysis of tumor cells (in vitro and in vivo).
• Bispecific antibodies selectively activates Vγ9+ γδ T cells and recruits γδT cells into cell-cell conjugate formation with tumor cells.